drugset / Trial / NCT01820260
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
RandomizedSequentialQuadruple-blindTreatment
Summary
To identify the Maximum Tolerated Dose levels of ingenol mebutate gel after once daily treatment for 2 or 3 consecutive days and to evaluate efficacy of ingenol mebutate gel in different doses after once daily treatment for 2 or 3 consecutive days compared to vehicle gel
Timeline
- Start
- 2013-04
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ingenol mebutate | Small molecule | 0.005 % | — |
| Subject | ingenol mebutate | Small molecule | 0.008 % | — |
| Subject | ingenol mebutate | Small molecule | 0.012 % | — |
| Subject | ingenol mebutate | Small molecule | 0.018 % | — |
| Subject | ingenol mebutate | Small molecule | 0.027 % | — |
| Subject | ingenol mebutate | Small molecule | 0.04 % | — |
| Subject | ingenol mebutate | Small molecule | 0.06 % | — |